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Alfonso Ielasi, MD,* Micaela Cioni, MD,‡ Kensuke Takagi, MD,*† Giedrius Davidavicius, MD,*
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ntonio Grimaldi, MD,‡ Ottavio Alfieri, MD,‡ Antonio Colombo, MD*†
ilan, Italy
Objectives The aim of this study was to analyze the short-term outcomes after transcatheter aortic
valve implantation with the Edwards Sapien THV (ESV), compared with the Sapien XT THV (SXT)
(Edwards Lifesciences, Irvine, California).
Background The SXT has been recently commercialized in Europe, but there are no studies analyz-
ing the efﬁcacy and safety of SXT, compared with ESV.
Methods All consecutive patients (n  120) who underwent transcatheter aortic valve implantation
in our center via the transfemoral approach with either ESV (n  66) or SXT (n  54). Valve Aca-
demic Research Consortium endpoints were used.
Results Mean age was 80  8 years, and mean Logistic-European System for Cardiac Operative
Risk Evaluation was 24.9  17.0. The ilio-femoral artery minimal lumen diameter was smaller in pa-
tients treated with the SXT (7.27  1.09 mm vs. 7.94  1.08 mm, p  0.002). Device success was
high in both groups (96.3% vs. 92.4%, p  0.45). Major vascular events were 3-fold lower in the SXT
group (11.1% vs. 33.3%, relative risk: 0.40, 95% conﬁdence interval: 0.28 to 0.57; p  0.004). Life-
threatening and major bleeding events were not signiﬁcantly different between groups (18.5% vs.
27.3% and 35.2% vs. 40.9%, respectively). The SXT group had a lower 30-day Valve Academic Re-
search Consortium combined safety endpoint (20.4% vs. 45.5%; relative risk: 0.44, 95% conﬁdence
interval: 0.24 to 0.80; p  0.004). The 30-day mortality was 1.7% (n  2). At 30 days, mean transaor-
tic gradient was approximately 10 mm Hg in both groups and the aortic regurgitation was mild-to-
moderate in 70.2% of SXT and 76.3% of ESV.
Conclusions The new SXT valve has the same short-term performance as the ESV but seems to be associ-
ated with a lower risk of major vascular complications and thus has a broader clinical application. (J Am Coll
Cardiol Intv 2011;4:743–50) © 2011 by the American College of Cardiology Foundation
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744Transcatheter aortic valve implantation (TAVI) is supe-
rior to conventional medical therapy for inoperable symp-
tomatic patients with severe aortic stenosis (1). The
improvement of technology and the introduction of
newer delivery systems that require smaller sheath sizes
have made the procedure safer and applicable to a wider
population of patients. The large size of the sheaths
required for valve delivery is the most important limita-
tion of this technique. Recently, the new Sapien XT
(Sapien XT THV [SXT], Edwards Lifesciences, Inc.,
Irvine, California) and NovaFlex delivery system received
CE-mark and became commercially available in Europe.
This new delivery system uses smaller-sized catheters
than the previous RetroFlex delivery system.
In the published data there are many studies that dem-
onstrate the efficacy and safety of the Edwards Sapien THV
(ESV) (Edwards Lifesciences), but there are no studies that
compare it with the new SXT valve (1–5). Thus, we
analyzed our experience with
transfemoral TAVI with the 2
different Edwards Sapien valves.
Methods
We included all consecutive pa-
tients undergoing TAVI in our
center via the transfemoral ap-
proach with the ESV from No-
vember 2007 to April 2010 and
SXT implanted since the device
became commercially available in
April 2010 until December 2010.
We compared patients treated
with ESV and SXT and analyzed
periprocedural and short-term
outcomes. Clinical follow-up was
performed by office visit at 30 days after the procedure.
Deﬁnitions. We used the recently described endpoint defi-
itions of the Valve Academic Research Consortium (6).
he following events were evaluated: device success, vascu-
ar complications, bleeding, acute kidney injury (AKI),
troke, myocardial infarction, death, prosthetic valve perfor-
ance, and the combined safety endpoint at 30 days.
ascular complications were divided into minor or major.
leeding complications were divided into life-threatening
r disabling bleeding and major bleeding. The AKI classi-
cation adopted the modified RIFLE (Risk, Injury, Failure,
oss, and End-stage kidney disease) criteria and includes 3
tages. Renal failure at baseline was defined as a creatinine
learance 60 ml/min. Stroke was further divided into major
nd minor. Prosthesis performance was evaluated at 1 month
y quantifying transaortic gradient and aortic regurgitation
AR). Aortic regurgitation was graded as being absent (0), mild
Abbreviations
and Acronyms
AKI  acute kidney injury
AR  aortic regurgitation
CI  confidence interval
ESV  Edwards Sapien THV
MLD  minimal lumen
diameter
MVE  major vascular
event(s)
OR  odds ratio
PPM  permanent
pacemaker
SXT  Sapien XT THV
TAVI  transcatheter aortic
valve implantation1), moderate (2), and severe (3 to 4) (7,8).Patient evaluation. All the patients have been evaluated by
a multidisciplinary heart team. Pre-procedural screening
consisted of: transthoracic and/or transesophageal echocardi-
ography, multislice computed tomography, and when required,
coronary angiography. Transthoracic echocardiography was
also performed at 24 to 48 h after procedure and at 1 month,
to assess prosthesis performance and left ventricular function.
The indication for TAVI was based on the presence of
symptomatic severe aortic stenosis (aortic valve area1 cm2
or mean gradient 40 mm Hg) and high surgical risk
features defined as a logistic European System for Cardiac
Operative Risk Evaluation (logistic-European System for
Cardiac Operative Risk Evaluation) 20%, Society of
Thoracic Surgeons Predicted Risk of Mortality 10%, or
associated comorbidities not captured by the 2 scores (e.g.,
prior thoracic radiotherapy, porcelain aorta, liver cirrhosis,
marked patient frailty) (9). There were also some patients
with symptomatic isolated severe AR, because of biopros-
thetic failure who were at high risk for reoperation. The
suitability for the transfemoral approach was determined by
evaluating the ilio-femoral artery diameters on multislice
computed tomography. A minimal lumen diameter (MLD)
of 7 mm was necessary for the 22-F and 8 mm for the 24-F
Retroflex delivery system but 6 mm for the Novaflex 18-F
and 6.5 mm for the 19-F in the absence of circumferential
calcifications.
All patients provided written informed consent for the
procedures and subsequent data collection and analysis for
research purposes.
Devices. The technical aspects of the procedure have been
escribed elsewhere by our group (2,10). The ESV is a
ovine pericardial leaflet valve mounted on a stainless steel
tent. The new SXT has modified scallop-shaped leaflets
hat provide superior hemodynamic properties and coapta-
ion. It is mounted on a cobalt-chromium alloy stent with
hinner struts, thus, giving it a lower profile. Both valves
ave 2 sizes: 23 and 26 mm. The RetroFlex 3 is a
alloon-expandable transcatheter delivery system where the
alve is crimped directly on the balloon. It allows introduc-
ion of the 23- or 26-mm ESV valve with 22-F (outer
iameter: 8.4 mm) and 24-F sheaths (outer diameter: 9.2
m). The NovaFlex delivery system allows a reduction in
heath size to 18-F (outer diameter: 7.2 mm) for the 23-mm
XT valve and 19-F (outer diameter: 7.5 mm) for the
6-mm valve. The valve is crimped on the catheter proxi-
ally to the inflatable balloon and is mounted on the
alloon in the descending aorta. The characteristics of the
evices are illustrated in Figure 1.
Statistical methods. Continuous variables are presented as
mean  SD, and categorical variables are presented as
frequencies (%). Normality of the distribution of continuous
variables was tested by means of the Kolmogorov-Smirnov
goodness-of-fit test. Continuous variables were compared
with the Student t test or Mann-Whitney U test where
p
p
(
t
u
e
t
c
p
A
b
p
m
wn.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 7 , 2 0 1 1 Mussardo et al.
J U L Y 2 0 1 1 : 7 4 3 – 5 0 Sapien XT Compared With Edwards Sapien Valve
745appropriate. Categorical variables were compared with chi-
square statistic or Fisher exact test where appropriate.
Exploratory multivariable analysis was performed to as-
sess the predictors of major vascular events (MVE) by
means of logistic regression analysis with purposeful selec-
tion of covariates and simultaneous entry (11). Candidate
variables included covariates associated at univariate analysis
with MVE (all with a p value 0.1) as well as variables
judged to be of clinical importance from previously pub-
lished data. The results are reported as adjusted odds ratios
(OR) with associated confidence intervals (CIs). The dis-
crimination and calibration ability of the multivariable
model was assessed by means of the C-statistic and the
Hosmer-Lemeshow statistic (12). A p value 0.05 was
considered statistically significant, and all reported p values
are 2-sided. Statistical analysis was performed with SPSS
Figure 1. Sapien XT and Edwards Sapien THV and Their Respective Deliver
The ﬁgure illustrates the characteristics of the Sapien XT and Edwards Sapien
Inc., Irvine, California). Sizes of the valves and diameters of the sheaths are shosoftware (version 16.0, SPSS, Inc., Chicago, Illinois). iResults
Baseline and procedural characteristics. During the study
eriod, 249 patients underwent TAVI at our center: 104
atients were treated with a Medtronic CoreValve
Medtronic, Inc., Minneapolis, Minnesota), and 145 were
reated with an Edwards prosthesis. Of the patients who
nderwent implantation of an Edwards prosthesis, 25 were
xcluded, because the approach was transapical (n  21) or
ransaxillary (n  4). Thus, the current study cohort
omprised 120 patients who underwent transfemoral im-
lantation of an Edwards prosthesis: 54 with SXT between
pril and December 2010, and 66 with ESV from Novem-
er 2007 to April 2010. Baseline clinical characteristics are
resented in Table 1. Fifty percent of the patients were
ale, and the mean age was 80  8 years. In 9 patients, the
tems
nd the NovaFlex and RetroFlex 3 delivery systems (Edwards Lifesciences,y Sys
valve andication for TAVI was a degenerated aortic bioprosthesis,
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746and 4 of them had isolated severe regurgitation. The
patients treated with the SXT had a smaller MLD of the
ilio-femoral arteries at the therapeutic access site than those
treated with the ESV (7.27 1.09 mm vs. 7.94 1.08 mm;
 0.002).
Procedural characteristics are shown in Table 2. The ratio
etween the outer diameter of the sheath size and MLD
f the vessel was significantly lower in the SXT group
1.03  0.15 vs. 1.13  0.14, p  0.001). Sedation and
ocal anesthesia were used in 76% of cases. However,
eneral anesthesia was used more frequently in the ESV
roup during the initial part of our TAVI experience
Table 1. Baseline Characteristics
Male
Age (yrs) 8
BMI (kg/m2) 2
BSA (m2) 1
Cerebrovascular disease
Coronary artery disease
Prior MI
Prior PCI
Prior CABG
Diabetes mellitus
Insulin therapy diabetes
Current smoker
Hypertension
Hypercholesterolemia
COPD
LVEF 5
LVEF 35%
PAPS 60 mm Hg
Aortic mean gradient (mm Hg) 5
Aortic annulus diameter (mm) 2
Severe aortic regurgitation
Porcelain aorta
Aortic prosthesis dysfunction
Chronic renal insufﬁciency
Dialysis
NYHA functional class III/IV
Angina
Syncope
Standard EuroScore 1
Logistic EuroScore 2
STS-PROM
STS morbidity and mortality 2
MLD of ilio-femoral vessels on therapeutic side (mm) 7
Values are n (%) or mean SD.
BMI bodymass index; BSA body surface area; CABG coronary
EuroScore  European System for Cardiac Operative Risk Evaluation
minimal lumen diameter; NYHA New York Heart Association; PAPS
tion; STS-PROM Society of Thoracic Surgeons predicted risk of mort37.9% vs. 5.6%, p  0.001). Percutaneous closure with arostar device (Abbott Vascular, Abbott, Park, Illinois)
acilitated by the cross-over technique described by our
roup (10) was used more frequently in SXT than in ESV
ases (98.1% vs. 83.3%, p  0.008). However, this
iscrepancy was expected, because at the beginning of our
xperience we preferred surgical closure of the femoral
rtery in patients with borderline vascular access. In
ddition, in 4 patients who underwent ESV implantation,
vascular complication precluded the possibility of using
he pre-closure device.
Periprocedural and 30-day clinical outcomes. The clinical
outcomes are shown in Table 3. The rate of device success
all
20)
Sapien XT
(n  54)
Edwards Sapien
(n  66) p Value
.0) 28 (51.9) 32 (48.5) 0.71
8.1 80.4 10.0 80.1 6.3 0.83
4.7 25.9 4.4 26.61 5.0 0.46
0.1 1.76 0.16 1.77 0.17 0.79
.7) 8 (14.8) 12 (18.2) 0.66
.3) 18 (33.3) 22 (33.3) 1.00
.3) 6 (11.1) 16 (24.2) 0.06
.5) 8 (14.8) 13 (19.7) 0.48
.3) 8 (14.8) 14 (21.2) 0.36
.7) 15 (27.8) 17 (25.8) 0.80
.5) 6 (11.1) 9 (13.6) 0.67
3) 3 (5.6) 1 (1.5) 0.32
.5) 35 (64.8) 40 (60.6) 0.63
.7) 32 (59.3) 36 (54.5) 0.60
.5) 13 (24.1) 26 (39.4) 0.07
12.0 53.4 12.7 51.2 11.4 0.31
.3) 6 (11.1) 10 (15.2) 0.51
.3) 7 (13) 9 (13.6) 0.91
17.4 54.8 16.6 56.3 18.2 0.63
1.6 23.3 1.7 22.7 1.5 0.08
.5) 8 (14.8) 7 (10.6) 0.48
.5) 9 (16.7) 12 (18.2) 0.82
5) 3 (5.6) 6 (9.1) 0.51
.7) 35 (64.8) 39 (59.1) 0.52
0) 3 (5.6) 3 (4.5) 1.00
.0) 38 (70.4) 46 (69.7) 0.93
.2) 17 (31.5) 12 (18.2) 0.09
.8) 12 (22.2) 13 (19.7) 0.73
2.7 10.4 2.8 11.0 2.6 0.24
17.0 22.9 18.0 26.5 1.6 0.25
5.5 7.1 6.1 7.2 5.0 0.86
13.4 28.1 15.1 30.4 11.9 0.36
1.13 7.27 1.09 7.94 1.08 0.002
bypass graft surgery; COPD chronic obstructive pulmonary disease;
left ventricle ejection fraction; MI  myocardial infarction; MLD 
ic pulmonary artery pressure; PCI percutaneous coronary interven-Over
(n  1
60 (50
0.2
6.3
.77
20 (16
40 (33
22 (18
21 (17
22 (18
32 (26
15 (12
4 (3.
75 (62
68 (56
39 (32
2.2
16 (13
16 (13
5.6
3.0
15 (12
21 (17
9 (7.
74 (61
6 (5.
84 (70
29 (24
25 (20
0.7
4.9
7.2
9.4
.63
artery
; LVEF 
systolwas high in both the SXT and ESV groups (96.3% vs.
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74792.4%, p  0.45). The overall rate of MVE was 23.3%, but
it was 3-fold lower in the SXT group (11.1% vs. 33.3%,
relative risk: 0.40, 95% CI: 0.28 to 0.57; p  0.004). In
nline Table 1, we have described in detail the MVE that
ccurred and their management. The rate of MVE in
atients who underwent percutaneous closure versus surgi-
al closure was (9.6% vs. 0%, p  1.00) in the SXT group
nd (34.4% vs. 20.0%, p  0.87) in the ESV group. The
minor vascular events were similar between the groups
(25.9% vs. 30.3%, p  0.59), and 18 of 34 (52.9%) of these
events were due to Prostar failure, which occurred with a
similar frequency in both groups (11.1% in SXT vs. 15% in
ESV, p  0.09). We observed 1 case of thoracic aortic
dissection after ESV implantation and 1 case of annulus
rupture and aortic dissection after SXT. The first underwent
emergency cardiac surgery but died at 46 days. The second
was treated by implanting another SXT to obtain hemosta-
sis, but this was unsuccessful and the patient died in the
catheterization laboratory. Life-threatening bleeding
(18.5% vs. 27.3%, p  0.25) and major bleeding (35.2% vs.
40.9%, p  0.52) were not significantly different between
groups. However, the need for blood transfusion showed a
trend for a lower rate in the SXT group (33.3% vs. 57.6%;
p  0.08). Four cases of cardiac tamponade were observed
in the SXT group, and 1 was observed in the ESV group.
The cardiac tamponades were treated by pericardiocen-
tesis in 3 cases, but 2 underwent cardiac surgery because
of aortic dissection (as described in the preceding text) or
rupture of the right atrial wall. The rate of AKI-stage 3
was 0 in the SXT group and 4.8% in the ESV group
(p  0.67). We observed only 2 cases of transient
ischemic attacks and 2 cases of major stroke. No peripro-
Table 2. Procedural Characteristics
Overall
(n  120
Prosthesis diameter 23 mm 48 (40.0)
Prosthesis diameter 26 mm 72 (60.0)
22-F sheath (RetroFlex delivery) 30 (25.0)
24-F sheath (RetroFlex delivery) 36 (30.0)
18-F sheath (NovaFlex delivery) 18 (15.0)
19-F sheath (NovaFlex delivery) 36 (30.0)
Sheath outer diameter/MLD 1.08 0.1
Valve-in-valve procedure 9 (7.5)
General anesthesia 28 (23.3)
Sedation 92 (76.7)
Surgical access closure as ﬁrst intention 6 (5.0)
Percutaneous closure 107/119* (8
Pre-valvuloplasty 107/119† (8
Post-dilation 6/119† (5
Values are n (%), mean SD, or n/N (%). *One patient died in laborato
the delivery to the aortic valve site.
MLDminimal lumen diameter.cedural myocardial infarction was observed. The rate of Spermanent pacemaker (PPM) implantation was 7.1%,
without a difference between the groups.
The 30-day mortality was 1.7% (n 2). Both patients died
after SXT implantation. One died some hours after the
procedure because of right ventricular failure; the other died in
the catheterization laboratory because of annular and aortic
dissection resulting in cardiac tamponade (described in the
preceding text). Furthermore, 1 patient died in hospital at 46
days after emergency surgery for a post-implantation ascending
aortic dissection (described in the preceding text).
The 30-day combined safety endpoint was lower in the
SXT group (20.4% vs. 45.5%, relative risk: 0.44, 95% CI:
0.24 to 0.80; p  0.004), mainly due to the lower rate of
MVE in this group.
Prosthesis performance. An echocardiographic evaluation
as performed at 30 days in 88% of patients. The mean
ransaortic gradient was approximately 10 mm Hg in both
roups. The AR was mild-to-moderate in 70.2% of SXT
nd 76.3% in ESV (p  0.48). Two patients had a mean
radient 20 mm Hg: 1 after ESV implantation, and 1
fter SXT implantation in a degenerated bioprosthesis. Four
atients had severe AR at 1 month after ESV implantation
Table 4).
Univariate and multivariable analyses. Results of the uni-
ariate and multivariable analyses are presented in Online
able 2. The univariate analysis identified 4 potential
redictors for MVE: SXT implantation (SXT vs. ESV;
R: 0.25, 95% CI: 0.09 to 0.67; p  0.004), ratio of
heath outer diameter/MLD (OR: 18.70, 95% CI: 1.04
o 336.41; p  0.04), body surface area (OR: 0.05, 95%
I: 0 to 0.80; p  0.03), and female sex (OR: 2.14, 95% CI:
.89 to 5.14; p  0.08). On the multivariable analyses, the
Sapien XT
(n  54)
Edwards Sapien
(n  66) p Value
18 (33.3) 30 (45.5) 0.17
36 (66.7) 36 (54.5) 0.17
— 30 (45.5) —
— 36 (54.5) —
18 (33.3) — —
36 (66.7) — —
1.03 0.15 1.13 0.14 0.001
3 (5.6) 6 (9.1) 0.46
3 (5.6) 25 (37.9) 0.001
51 (94.4) 41 (62.1) 0.001
1 (1.9) 5 (7.6) 0.22
52/53* (98.1) 55/66 (83.3) 0.008
51/54 (94.4) 56/65† (86.2) 0.13
3/54 (5.6) 3/65† (4.6) 0.81
atient valvuloplasty was not attempted because of failure to advance)
5
9.9)
9.9)
.0)
ry; †1 pXT (OR: 0.25, 95% CI: 0.09 to 0.67; p  0.006) emerged
H
w
v
i
D
nt ische
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 7 , 2 0 1 1
J U L Y 2 0 1 1 : 7 4 3 – 5 0
Mussardo et al.
Sapien XT Compared With Edwards Sapien Valve
748as the only significant independent predictor of reduced
MVE, whereas female sex showed a trend for increased
MVE (OR: 2.16, 95% CI: 0.87 to 5.35; p  0.09). The
osmer-Lemeshow goodness-of-fit test probability value
as 0.99, confirming good calibration and fit of the multi-
ariable model. The C-statistic for the final model was 0.7,
ndicating acceptable discrimination.
iscussion
The main findings of this study are: 1) introduction of the
Table 3. Periprocedural and 30-Day Clinical Outcome
Overall
(n  120)
Periprocedural and in-hospital clinical outcomes
Device success 113 (94.2)
Any vascular complication 62 (51.7)
Major vascular complication 28 (23.3)
Minor vascular complication 34 (28.3)
Aortic dissection 2 (1.7)
Cardiac tamponade 5 (4.2)
Life-threatening bleeding 28 (23.3)
Major bleeding 46 (38.3)
Blood transfusion 56 (46.7)
Valve embolization/migration 0 (0)
Second valve implantation 1 (0.8)
Coronary obstruction 1 (0.8)
Periprocedural MI 0 (0)
Emergency cardiac surgery 2 (1.7)
PPM implantation 8/112* (7.1)
AKI 38/114† (33.3
AKI stage 1 28/114† (24.6
AKI stage 2 6/114† (5.3)
AKI stage 3 4/114† (3.5)
TIA 2 (1.7)
Major stroke 2 (1.7)
Death 3 (2.5)
Repeat procedure for valve relating
dysfunction
0 (0)
Clinical outcomes at 30 days
TIA 2 (1.7)
Death 2 (1.7)
Cardiac death 2 (1.7)
Major stroke 2 (1.7)
Life-threatening bleeding 27 (22.5)
AKI stage 3 4/114† (3.5)
MI 0 (0)
Major vascular complication 28 (23.3)
Repeat procedure for valve-related
dysfunction
0 (0)
VARC combined safety endpoint 41 (34.2)
Values are n (%) or n/N (%). *Eight patients already had a permanent
AKI acute kidney injury; MImyocardial infarction; TIA transieSXT valve and NovaFlex delivery allowed the performanceof transfemoral TAVI in patients with more severe periph-
eral artery disease with a reduction of MVE; 2) transfemoral
TAVI with both the SXT and ESV was associated with a
high device success rate and relatively low periprocedural
and short-term outcomes in high-risk elderly patients; and
3) the SXT seems to have the same short-term performance
as the ESV.
The transfemoral route is at the present time limited by
the large diameters of the delivery sheaths required and the
inadequate diameters of the ilio-femoral vessels to accom-
modate these sheaths. Because the prevalence of peripheral
Sapien XT
(n  54)
Edwards Sapien
(n  66) p Value
52 (96.3) 61 (92.4) 0.45
20 (37) 42 (63.6) 0.004
6 (11.1) 22 (33.3) 0.004
14 (25.9) 20 (30.3) 0.59
1 (1.9) 1 (1.5) 1.00
4 (7.4) 1 (1.5) 0.17
10 (18.5) 18 (27.3) 0.25
19 (35.2) 27 (40.9) 0.52
18 (33.3) 38 (57.6) 0.08
0 (0) 0 (0)
1 (1.9) 0 (0) 0.45
1 (1.9) 0 (0) 0.45
0 (0) 0 (0)
1 (1.9) 1 (1.5) 1.00
3/51 (5.9) 5/61 (8.2) 0.72
13/51 (25.5) 25/63 (39.7) 0.11
12/51 (23.5) 16/63 (25.4) 0.81
0/51 6/63 (9.5) 0.03
0/51 3/63 (4.8) 0.67
1 (1.9) 1 (1.5) 1.00
1 (1.9) 1 (1.5) 1.00
2 (3.7) 1 (1.5) 0.58
0 (0) 0 (0)
1 (1.9) 1 (1.5) 1.00
2 (3.7) 0 (0) 0.20
2 (3.7) 0 (0) 0.20
1 (1.9) 1 (1.5) 1.00
10 (18.5) 17 (25.8) 0.34
0/51 3/63 (4.8) 0.67
0 (0) 0 (0)
6 (11.1) 22 (33.3) 0.004
0 (0) 0 (0)
11 (20.4) 30 (45.5) 0.004
ker (PPM); †6 patients were already in dialysis treatment.
mic attack; VARC Valve Academic Research Consortium.s
)
)
pacemaarterial disease is high in this population, many patients are
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749not suitable for transfemoral TAVI. To avoid this problem,
companies are working to produce devices with smaller sizes
that will make this procedure a viable option in more
patients; at the same time, they could reduce the rate of
vascular complications, which are the most frequent cause of
morbidity after TAVI. Until recently, there has not been a
uniform definition of post-TAVI events in the published
data, but recently Leon et al. (6) published the new Valve
Academic Research Consortium endpoint definitions. As
can be seen in Online Table 3, there is a wide variation (8%
to 16%) in the incidence of MVE in transfemoral TAVI
with the Sapien valves (1,3–5,13–16).
In our study, the incidence of total MVE was 23.3%.
However, due to the lack of a standardized definition for
vascular complications and the different definitions used in
previous studies, it is difficult to make any direct compari-
sons. We observed a significantly lower rate of MVE in
patients treated with SXT compared with ESV (11.1% vs.
33.3%, p 0.004). Moreover, we found that the ratio of the
sheath outer diameter size to vessel MLD was a univariate
predictor of MVE (1.14  0.15 vs. 1.07  0.15, p  0.04).
Furthermore, this ratio was lower in the SXT group than in
the ESV group (1.03  0.15 vs. 1.13  0.14, p  0.001).
This suggests that vascular injury increases as the operator
attempts the procedure with diseased peripheral vessels that
have an inadequate size for the sheaths. Thus, the SXT
might have a broader clinical application, because it allows
TAVI in patients with more severe peripheral vascular
disease by reducing the ratio of sheath outer diameter size to
vessel MLD but, at the same time, lowering the risk of
MVE. The lower MVE risk with SXT was confirmed on
multivariable analysis.
Bleeding is an important safety endpoint in evaluating the
TAVI procedure, but similar to MVE, the definitions of
bleeding are variable (1,13,16). In our study, the incidence
of life-threatening bleeding and major bleeding seems not
to differ significantly between the groups, but we observed a
trend for a lower need for blood transfusion in the SXT
group (33.3% vs. 57.6%). Interestingly, there was a trend of
Table 4. Echocardiographic Data at 1 Month
Overall
(n  106)
Mean gradient (mm Hg) 9.8 3.9
Peak gradient (mm Hg) 17.9 6.4
AR 0 24 (22.6)
AR 1 50 (47.2)
AR 2 28 (26.4)
AR 3 4 (3.8)
LVEF % 53.2 9.1
Values are mean SD or n (%).
AR aortic regurgitation; LVEF left ventricle ejection fraction.more cases of cardiac tamponade in the SXT group. We tbelieve that this complication could not be attributed to the
new delivery system or to changes in the technical aspects of
the procedure but to the recent introduction and training of
new operators in our team.
However, even if the MVE were more frequent in the ESV
group, we observed only 3 in-hospital deaths (2.5%) and a low
rate of 30-day mortality (1.7%), without a significant difference
between the 2 groups. As discussed in the preceding text, only
2 patients died because of vascular complications. We believe
that the low rate of early mortality in our population, despite
the high rate of vascular events, is due to the ability of our
operators to promptly treat such complications. In addition,
the use of a lower-diameter sheath decreased the occurrence of
vascular complications. We think that expertise of TAVI
operators in the percutaneous treatment of vascular complica-
tions is paramount for reducing mortality in this high-risk
patient group.
As already described in published data, the rate of PPM
is low after Edwards Sapien valve implantation compared
with the CoreValve (Medtronic) (16). In this study we
didn’t find any difference in the need of PPM in the ESV
and SXT groups, and we have confirmed a low rate in both
groups (approximately 8%).
Finally, this study demonstrated that the SXT has similar
performance at 1-month compared with the ESV. The rate
of device success was high with both valves, and the grade of
AR in both groups was mainly mild or moderate; mean-
while, the mean transaortic gradient was approximately 10
mm Hg.
Study limitations. The main limitation of this study is its
etrospective observational design and lack of randomiza-
ion. However, when the SXT was introduced in Europe,
he ESV became no longer commercially available. We
hink that these data are important and might provide useful
nformation with regard to sample size, should the U.S.
ood and Drug Administration require a randomized trial
efore approval of the new SXT valve. Another limitation
ould be the different level of experience of the operators
ien XT
 47)
Edwards Sapien
(n  59) p Value
 3.6 9.9 4.0 0.82
 6.6 18.4 6.2 0.82
(29.8) 10 (16.9) 0.11
(34.0) 34 (57.6) 0.01
(36.2) 11 (18.6) 0.04
(0) 4 (6.8) 0.12
 8.1 52.3 9.9 0.29Sap
(n
9.7
17.2
14
16
17
0
54.2hrough the study period.
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750Conclusions
TAVI with an Edwards prosthesis was associated with high
implantation success and low early mortality in patients at
high-risk for surgery, with the 2 prostheses having a similar
short-term performance. The requirement for a smaller
ilio-femoral diameter and lower risk of major vascular
complications extended the clinical applications of the SXT
system.
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